{"BACKGROUND:": [0], "Patients": [1], "with": [2, 36, 53, 63, 74, 127, 209, 213, 228], "advanced": [3, 37], "biliary": [4, 38, 59], "tract": [5, 39, 60], "cancer": [6, 61], "have": [7], "a": [8], "poor": [9], "prognosis,": [10], "and": [11, 112, 140, 181, 211, 226, 230, 245, 260], "first-line": [12], "standard": [13], "of": [14, 130, 217, 267], "care": [15], "(gemcitabine": [16], "plus": [17, 32, 76, 235, 243, 250], "cisplatin)": [18], "has": [19], "remained": [20], "unchanged": [21], "for": [22, 34, 78, 153, 179, 188, 193], "more": [23], "than": [24], "10": [25], "years.": [26], "The": [27, 95, 150, 166, 190, 215, 264], "TOPAZ-1": [28], "trial": [29], "evaluated": [30], "durvalumab": [31, 69, 85, 122, 138, 180, 210, 229], "chemotherapy": [33, 236, 244, 251], "patients": [35, 52, 117, 134, 142], "cancer.": [40], "METHODS:": [41], "In": [42], "this": [43], "double-blind,": [44], "placebo-controlled,": [45], "phase": [46], "3": [47, 219], "study,": [48], "we": [49], "randomly": [50, 119], "assigned": [51, 120], "previously": [54], "untreated": [55], "unresectable": [56], "or": [57, 62, 70, 86, 92, 124, 220], "metastatic": [58], "recurrent": [64], "disease": [65, 90], "1:1": [66], "to": [67, 80, 99, 121, 163, 177, 186, 201], "receive": [68], "placebo": [71, 87, 125, 146, 242, 249], "in": [72, 136, 144, 252], "combination": [73], "gemcitabine": [75], "cisplatin": [77], "up": [79], "eight": [81], "cycles,": [82], "followed": [83], "by": [84, 275], "monotherapy": [88], "until": [89], "progression": [91], "unacceptable": [93], "toxicity.": [94], "primary": [96], "objective": [97, 109, 261], "was": [98, 156, 172, 196], "assess": [100], "overall": [101, 154, 169, 239], "survival.": [102], "Secondary": [103], "end": [104, 255], "points": [105, 256], "included": [106], "progression-free": [107, 194, 258], "survival,": [108], "response": [110, 205, 262], "rate,": [111], "safety.": [113], "RESULTS:": [114], "Overall,": [115], "685": [116], "were": [118, 207, 224, 272], "(n=341)": [123], "(n=344)": [126], "chemotherapy.": [128], "As": [129], "data": [131], "cutoff,": [132], "198": [133], "(58.1%)": [135], "the": [137, 145, 268], "group": [139, 147], "226": [141], "(65.7%)": [143], "had": [148], "died.": [149], "hazard": [151, 191], "ratio": [152, 192], "survival": [155, 170, 195, 240, 259], "0.80": [157], "(95%": [158, 174, 183, 198], "confidence": [159], "interval": [160], "[CI],": [161], "0.66": [162], "0.97;": [164], "P=0.021).": [165], "estimated": [167], "24-month": [168], "rate": [171], "24.9%": [173], "CI,": [175, 184, 199], "17.9": [176], "32.5)": [178], "10.4%": [182], "4.7": [185], "18.8)": [187], "placebo.": [189, 214], "0.75": [197], "0.63": [200], "0.89;": [202], "P=0.001).": [203], "Objective": [204], "rates": [206], "26.7%": [208], "18.7%": [212], "incidences": [216], "grade": [218], "4": [221], "adverse": [222], "events": [223], "75.7%": [225], "77.8%": [227], "placebo,": [231], "respectively.": [232], "CONCLUSIONS:": [233], "Durvalumab": [234], "significantly": [237], "improved": [238], "versus": [241, 248], "showed": [246], "improvements": [247], "prespecified": [253], "secondary": [254], "including": [257], "rate.": [263], "safety": [265], "profiles": [266], "two": [269], "treatment": [270], "groups": [271], "similar.": [273], "(Funded": [274], "AstraZeneca;": [276], "ClinicalTrials.gov": [277], "number,": [278], "NCT03875235.)": [279]}